|1.||Neves, Gilda: 4 articles (01/2013 - 03/2008)|
|2.||Rates, Stela M K: 4 articles (01/2013 - 03/2008)|
|3.||Fraga, Carlos A M: 4 articles (01/2013 - 03/2008)|
|4.||Barreiro, Eliezer J: 4 articles (01/2013 - 03/2008)|
|5.||Noël, François: 3 articles (01/2013 - 03/2010)|
|6.||Betti, Andresa H: 2 articles (01/2013 - 03/2008)|
|7.||Antonio, Camila B: 2 articles (01/2013 - 03/2010)|
|8.||Filipek, Barbara: 2 articles (04/2012 - 01/2011)|
|9.||Zygmunt, Małgorzata: 2 articles (04/2012 - 01/2011)|
|10.||Menegatti, Ricardo: 2 articles (05/2010 - 03/2010)|
|1.||Schizophrenia (Dementia Praecox)
03/01/2010 - "We described herein the design, synthesis, and pharmacological evaluation of N-phenylpiperazine heterocyclic derivatives as multi-target compounds potentially useful for the treatment of schizophrenia. "
01/15/2013 - "New insights into pharmacological profile of LASSBio-579, a multi-target N-phenylpiperazine derivative active on animal models of schizophrenia."
05/01/2010 - "LASSBio-581 is a N-phenylpiperazine derivative designed for the treatment of schizophrenia. "
03/01/2008 - "Previous studies have demonstrated that LASSBio-579 and LASSBio-581, two N-phenylpiperazine derivatives designed for the treatment of schizophrenia, are presynaptic dopamine D(2) receptor agonists that induce a hypothermic effect in mice that is not mediated by dopamine receptor activation. "
01/01/1988 - "The present study was undertaken to elucidate the effects of a new synthesized phenylpiperazine derivative SGB-1534 on mean arterial blood pressure and heart rate in stroke-prone spontaneously hypertensive rats(SHRSP). "
01/01/1988 - "Effects of SGB-1534, a new synthesized phenylpiperazine derivative, on blood pressure and heart rate in stroke-prone spontaneously hypertensive rats."
|4.||Parkinson Disease (Parkinson's Disease)
|5.||Alzheimer Disease (Alzheimer's Disease)
09/01/2008 - "This study intended to provide a patient profile for trazodone (a triazolopyridine-derivative of phenylpiperazine) prescription in everyday clinical practice in patients with Alzheimer's disease (AD), and to describe clinical evaluation and the impact on caregiver burden at a 6-month follow-up. "
|1.||Dopamine Receptors (Dopamine Receptor)
|5.||Levodopa (L Dopa)
|9.||Calcium-Calmodulin-Dependent Protein Kinase Type 2